ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
View Top Employees from ARCA biopharma, Inc.Website | http://www.arcabio.com |
Ticker | ABIO |
Revenue | $4 million |
Funding | $42 million |
Employees | 25 (20 on RocketReach) |
Founded | 2004 |
Address | 10170 Church Ranch Way Suite 100, Westminster, Colorado 80021, US |
Phone | (720) 940-2100 |
Fax | (720) 208-9261 |
Technologies |
JavaScript,
HTML,
PHP
+8 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Drug Discovery |
Web Rank | 22 Million |
Competitors | Centrose LLC, Eiger BioPharmaceuticals, HARBOUR BIOMED, Medesis Pharma, TARIS Bio |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular ARCA biopharma, Inc. employee's phone or email?
The ARCA biopharma, Inc. annual revenue was $4 million in 2024.
Tom Keuer is the COO of ARCA biopharma, Inc..
20 people are employed at ARCA biopharma, Inc..
ARCA biopharma, Inc. is based in Westminster, Colorado.
The NAICS codes for ARCA biopharma, Inc. are [32, 3254, 32541, 325].
The SIC codes for ARCA biopharma, Inc. are [283, 28].